Perseus Proteomics Inc. (TYO:4882)
Japan
· Delayed Price · Currency is JPY 446.00
+15.00 (3.48%)
May 16, 2025, 3:30 PM JST
Perseus Proteomics Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2018 - 2019 |
Cash & Equivalents | 1,879 | 1,541 | 2,444 | 3,214 | 1,069 | 482 | Upgrade
|
Cash & Short-Term Investments | 1,879 | 1,541 | 2,444 | 3,214 | 1,069 | 482 | Upgrade
|
Cash Growth | 12.98% | -36.95% | -23.96% | 200.65% | 121.78% | -56.18% | Upgrade
|
Accounts Receivable | 13.53 | 13 | 9 | 10 | 8 | 9 | Upgrade
|
Other Receivables | 40.48 | 70 | 41 | 35 | 21 | 27 | Upgrade
|
Receivables | 54.01 | 83 | 50 | 45 | 29 | 36 | Upgrade
|
Inventory | 5.83 | 4 | 3 | 3 | 1 | 1 | Upgrade
|
Prepaid Expenses | 10.99 | 5 | 7 | 4 | 4 | 4 | Upgrade
|
Other Current Assets | 3.48 | 17 | 10 | 24 | 5 | 15 | Upgrade
|
Total Current Assets | 1,953 | 1,650 | 2,514 | 3,290 | 1,108 | 538 | Upgrade
|
Long-Term Investments | 42.86 | 42 | 51 | 9 | 9 | 9 | Upgrade
|
Other Long-Term Assets | 0 | 1 | 1 | 1 | 1 | - | Upgrade
|
Total Assets | 1,996 | 1,693 | 2,566 | 3,300 | 1,118 | 547 | Upgrade
|
Accounts Payable | 29.38 | 1 | 1 | - | 1 | - | Upgrade
|
Accrued Expenses | 70.99 | 57 | 28 | 11 | 8 | 6 | Upgrade
|
Current Income Taxes Payable | 10.96 | 66 | 66 | 134 | 24 | 53 | Upgrade
|
Other Current Liabilities | 4.08 | 4 | 16 | 3 | 1 | 2 | Upgrade
|
Total Current Liabilities | 115.4 | 128 | 111 | 148 | 34 | 61 | Upgrade
|
Other Long-Term Liabilities | 241.49 | 167 | 59 | - | 1 | 1 | Upgrade
|
Total Liabilities | 356.89 | 295 | 170 | 148 | 35 | 62 | Upgrade
|
Common Stock | 2,436 | 1,971 | 1,939 | 1,939 | 604 | 799 | Upgrade
|
Additional Paid-In Capital | 2,722 | 2,256 | 2,225 | 2,225 | 889 | 1,057 | Upgrade
|
Retained Earnings | -3,598 | -2,903 | -1,799 | -1,012 | -413 | -1,371 | Upgrade
|
Comprehensive Income & Other | 79.22 | 74 | 31 | - | 3 | - | Upgrade
|
Shareholders' Equity | 1,639 | 1,398 | 2,396 | 3,152 | 1,083 | 485 | Upgrade
|
Total Liabilities & Equity | 1,996 | 1,693 | 2,566 | 3,300 | 1,118 | 547 | Upgrade
|
Net Cash (Debt) | 1,879 | 1,541 | 2,444 | 3,214 | 1,069 | 482 | Upgrade
|
Net Cash Growth | 12.98% | -36.95% | -23.96% | 200.65% | 121.78% | -56.18% | Upgrade
|
Net Cash Per Share | 127.47 | 130.72 | 207.83 | 292.27 | 152.72 | 78.42 | Upgrade
|
Filing Date Shares Outstanding | 14.74 | 11.85 | 11.76 | 11.75 | 8.36 | 6.15 | Upgrade
|
Total Common Shares Outstanding | 14.74 | 11.85 | 11.76 | 11.75 | 8.36 | 6.15 | Upgrade
|
Working Capital | 1,838 | 1,522 | 2,403 | 3,142 | 1,074 | 477 | Upgrade
|
Book Value Per Share | 111.21 | 118.00 | 203.75 | 268.36 | 129.53 | 78.91 | Upgrade
|
Tangible Book Value | 1,639 | 1,398 | 2,396 | 3,152 | 1,083 | 485 | Upgrade
|
Tangible Book Value Per Share | 111.21 | 118.00 | 203.75 | 268.36 | 129.53 | 78.91 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.